Q1 2025 Ascendis Pharma A/S Earnings Call Transcript
Key Points
- Ascendis Pharma AS (ASND) reported strong revenue growth for YORVIPATH, with first-quarter revenue increasing significantly to EUR 44.7 million, driven by a successful US launch.
- SKYTROFA achieved EUR 51 million in revenue for Q1, maintaining a stable market share and pricing, with expectations for continued growth.
- The company has made significant progress in regulatory approvals, with TransCon PTH approved in the US and Europe for hypoparathyroidism, and TransCon CNP submitted for FDA review.
- YORVIPATH has been prescribed by over 1,000 unique healthcare providers in the US, indicating strong market penetration and acceptance.
- Ascendis Pharma AS (ASND) is on track to become cash flow positive, supported by a growing revenue base and strategic product launches.
- R&D expenses increased to EUR 86.6 million in Q1, up from EUR 70.7 million in the same period last year, impacting overall profitability.
- SG&A expenses rose significantly to EUR 101 million, primarily due to global commercial expansion, which may pressure margins.
- The company faces challenges in achieving 100% reimbursement approval for YORVIPATH, with expectations of 70-80% reimbursement success.
- Revenue for SKYTROFA in the US was negatively impacted by seasonal factors, including channel inventory reductions and higher co-pay assistance.
- The company is not providing specific revenue guidance for SKYTROFA or YORVIPATH, creating uncertainty for investors regarding future financial performance.
Ladies and gentlemen, thank you for standing by and welcome to Ascendis Pharma first-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would like now to turn the conference over to Scott Smith, Vice President and Chief Financial Officer. Please go ahead, sir.
/- -
Thank you so much, operator, and thank you, everyone, for joining our first-quarter 2025 financial results conference call. I'm Scott Smith, Chief Financial Officer at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Sherrie Glass, Chief Business Officer; Jay Wu, Executive Vice President and President Ascendis US; and Aimee Shu, Chief Medical Officer.
Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the Safe
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
